BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 1998

View Archived Issues

PAF antagonists in the treatment of asthma: promise or hype?

Read More

Onconase and proteasome inhibitors have synergistic antitumor activity, even in resistant tumors

Read More

Ligand files new drug submission for Panretin Gel in Canada

Read More

Coulter initiates expanded access program for Bexxar

Read More

HER2 diagnostic test approved in U.S.; will help identify candidates for Herceptin therapy

Read More

Targeted Genetics initiates phase II trials for proprietary gene therapy compound

Read More

Orphan Medical's Busulfex Injection granted priority review

Read More

Yoshitomi: Annual Report 1998

Read More

New orally active antitumor platinum complexes synthesized at SS Pharm.

Read More

Gruenenthal develops new opioid analgesics

Read More

Akzo describes selective 5-HT2C agonists for depression and other CNS disorders

Read More

Dual TxA2 antagonists and NO donors and their use disclosed by ADIR

Read More

New series of beta-agonists in early development at Yamanouchi

Read More

Use of rPAF-AH in necrotizing colitis, ARDS and acute pancreatitis

Read More

Elan completes acquisition of NanoSystems

Read More

ThromboSol effectively preserves platelet function and cell recovery in in vivo study

Read More

Radiolabeled peptide from Diatide effectively pinpoints site of infection

Read More

Long-term ETA receptor blockade shows detrimental effects on LV remodeling

Read More

Genotyping accurately predicts response to treatment with 5-LO inhibitor

Read More

ZK-137316: chronic, low-dose regimen prevents pregnancy in monkeys with little cycle disruption

Read More

Anti-IgE antibody in the treatment of asthma: an interesting theory is validated

Read More

Lilly to pursue new indication for Zyprexa despite FDA nonapprovable letter

Read More

Novel antiepileptic agent developed by SK enters clinical trials

Read More

Actonel now available for treatment of Paget's disease

Read More

Pivotal trial of exisulind for prostate cancer recurrence fully enrolled

Read More

InKine colonic purgative proceeds to phase III trials

Read More

Cytogen anticipates selection of new marketing partner for Quadramet

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing